Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...

Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...

In this video, Aruna Padmanabhan, MD, discusses the evaluation of PI3K inhibitor combinations as first-line treatment for patients with metastatic breast cancer.

Overall, 49 patients (20 patients in Z1G and 29 in Z1H) were included in the primary efficacy analyses. The objective response rates in both cohorts were 0% (Z1G; 90% CI, 0 to 13.9) and 3.4% (Z1H; 90% ...

It’s been a minute since Lifehacker looked at the slang of Generation Z—long enough that Generation Alpha has had time to develop and spread some of its own special buzzwords and jargon.

An expanded biochemical analysis of purified mutant PI3K complexes across the canonical membrane signaling landscape will be important for deciphering how competition between wild-type and mutant ...

The drug candidate is administered through oral route and targets phosphatidylinositol 3-kinase (PI3K) alpha. It was also under development for skin rash in patients with metastatic breast cancer, ...

The recent acquisition of Scorpion Therapeutics for approximately $2.5 billion is set to bolster Eli Lilly's oncology portfolio, particularly in advancing PI3K-alpha mutant selective therapies for ...